| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss before noncontrolling interest | ||||||
-21,938 | -23,845 | -54,647 | -55,353 | -41,107 | -36,101 | -48,203 |
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: | ||||||
Gain on disposal of property and equipment, net | ||||||
288 | 12 | 11 | 2 | 7 | -34 | -21 |
Depreciation expense | ||||||
39 | 218 | 197 | 265 | 501 | 864 | 1,086 |
Share-based compensation expense | ||||||
1,518 | 2,676 | 3,645 | 2,641 | 859 | - | - |
Share-based compensation expense - related party Series F | ||||||
- | - | - | - | - | - | 2,921 |
Change in fair value of contingent distribution | ||||||
- | - | - | - | 695 | - | - |
Change in fair value of warrants, related party | ||||||
-827 | 638 | 190 | - | - | - | - |
Amortization of debt discount | ||||||
532 | 1,014 | 1,029 | 154 | - | - | - |
Amortization of debt discount related party | ||||||
- | - | - | - | - | 4,773 | 10,181 |
Non-cash interest expense distribution payable | ||||||
- | - | - | - | 27 | - | - |
Amortization of deferred financing costs | ||||||
- | - | - | - | - | 145 | 290 |
Impairment loss on carrying value of land | ||||||
- | - | - | - | 48 | 488 | - |
Change in fair value of derivative liability - related party | ||||||
- | - | - | - | - | - | 213 |
Bad debt (recovery) expense related party | ||||||
- | - | - | - | -3 | 633 | 656 |
Impairment loss of marketable securities related party | ||||||
- | - | - | - | - | 30 | - |
Change in fair value of marketable securities related party | ||||||
- | - | - | - | - | 39 | 14 |
Changes in assets and liabilities: | ||||||
Accounts receivable | ||||||
5 | -8,000 | 8,000 | -69 | 69 | 733 | -3 |
Prepaid expenses and other assets | ||||||
-732 | 1,135 | -170 | -502 | 1,020 | -62 | 95 |
Employee loans receivable – related party | ||||||
- | - | - | -49 | -12 | 43 | - |
Receivable due from a related party | ||||||
- | - | - | - | - | 623 | 575 |
Note receivable | ||||||
- | - | - | - | 20 | 231 | 231 |
Long-term deposits | ||||||
408 | -2,256 | 358 | 261 | 1,598 | - | - |
Other long-term assets | ||||||
- | - | - | - | - | 4 | 5 |
Accounts payable and accrued expenses | ||||||
-618 | -6,199 | 2,448 | 4,786 | 2,930 | -2,324 | -6,284 |
Accounts payable and accrued expenses – related party | ||||||
- | - | - | -880 | 2,458 | 2,144 | -1,608 |
Contract liabilities | ||||||
-1,755 | -10,435 | 10,753 | -198 | - | - | - |
Deferred revenue | ||||||
- | - | - | - | 219 | - | - |
Other liabilities | ||||||
- | -32 | 24 | 19 | -871 | 68 | -26 |
Net cash used in operating activities | ||||||
-23,018 | -26,856 | -44,560 | -48,209 | - | - | - |
Cash flows from investing activities: | ||||||
Net cash used in operating activities | ||||||
- | - | - | - | -36,946 | -30,779 | -41,684 |
Proceeds from sale of assets | ||||||
312 | 12 | 32 | 4 | 25 | 334 | 25 |
Expenses paid related to disposal of HPCTC related party | ||||||
- | - | - | - | - | 140 | - |
Purchases of property and equipment | ||||||
70 | 5 | 57 | 87 | 104 | 33 | 181 |
Net cash provided by (used in) investing activities | ||||||
242 | 7 | -25 | -83 | - | - | - |
Cash flows from financing activities: | ||||||
Proceeds from issuance of Class A Common Stock to a related party under the Letter Agreements | ||||||
27,500 | 21,500 | - | - | - | - | - |
Issuance of preferred units - related party | ||||||
- | - | - | - | - | - | 5 |
Proceeds from issuance of Class A Common Stock, net of offering costs | ||||||
5,443 | - | - | - | - | - | 6 |
Proceeds from debt issuance | ||||||
500 | 500 | 7,500 | 12,500 | - | - | - |
Repurchase of TTP preferred common member units and warrants related party | ||||||
- | - | - | - | - | 2,500 | - |
Debt issuance costs | ||||||
- | - | - | 673 | - | - | - |
Net cash provided by (used in) investing activities | ||||||
- | - | - | - | -79 | 161 | -156 |
Proceeds from issuance of vTv Therapeutics Inc. Class A Common Stock sold in initial public offering, net of offering costs | ||||||
- | - | - | - | 105,773 | - | - |
Repayment of notes payable | ||||||
10,573 | 5,388 | - | 33 | - | - | - |
Net cash provided by financing activities | ||||||
22,870 | 16,612 | 7,500 | 11,794 | - | - | - |
Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | ||||||
94 | -10,237 | -37,085 | -36,498 | - | - | - |
Payment of offering costs related party | ||||||
- | - | - | - | 1,329 | - | - |
Proceeds from debt issuance related party | ||||||
- | - | - | - | 19,289 | 33,561 | 39,175 |
Repayment of long-term obligations | ||||||
- | - | - | - | 89 | 148 | - |
Repayment of debt | ||||||
- | - | - | - | - | - | -141 |
Net cash provided by financing activities | ||||||
- | - | - | - | 123,644 | 30,913 | 40,805 |
Net decrease in cash and cash equivalents | ||||||
- | - | - | - | 86,619 | 295 | -1,035 |
Supplemental cash flow information: | ||||||
Cash paid for interest | ||||||
1,295 | 2,276 | 2,064 | 242 | - | - | - |
Cash paid for income taxes | ||||||
100 | 1,000 | - | - | - | - | - |
Cash paid for interest | ||||||
- | - | - | - | 75 | 142 | 192 |
Non-cash activities: | ||||||
Receipt of investment as partial consideration for license agreement | ||||||
- | - | 2,480 | - | - | - | - |
Right-of-use assets obtained in exchange for lease obligations | ||||||
548 | - | - | - | - | - | - |
Leasehold improvements obtained in exchange for lease obligations | ||||||
384 | - | - | - | - | - | - |
Change in carrying value of net assets and liabilities not transferred to vTv Therapeutics, LLC as part of the Reorganization Transactions | ||||||
- | - | - | - | 2,747 | - | - |
Change in redemption value of noncontrolling interest | ||||||
13,405 | 52,873 | -47,428 | -3,149 | -190,598 | - | - |
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock | ||||||
- | 151 | - | 3,164 | 12,461 | - | - |
Issuance of Letter Agreements and warrants to purchase vTv Therapeutics Inc. Class A Common Stock to a related party | ||||||
992 | 1,308 | 302 | - | - | - | - |
Issuance of warrants to purchase vTv Therapeutics Inc. Class A Common Stock | ||||||
- | - | - | 923 | - | - | - |
Repurchase of TTP and HPP preferred units, common membership units and warrants, in exchange for HPCTC and other liabilities, net of cash exchanged related party | ||||||
- | - | - | - | - | 40,351 | - |
Deemed contribution from related party in a debt extinguishment related party | ||||||
- | - | - | - | - | 18,733 | 6,853 |
Issuance of TTP Series F redeemable preferred units in exchange for debt related party | ||||||
- | - | - | - | - | 74,000 | 33,458 |
Redeemable Noncontrolling Interest [Member] | ||||||
Change in redemption value of noncontrolling interest | ||||||
-13,405 | -52,873 | 47,428 | 3,149 | - | - | - |